pbm glp-1 news Big policy shift in obesity medicine. Starting July 1, 2026, Medicare will launch a temporary “GLP-1 Bridge” program allowing eligible patients to access drugs like Zepbound and Wegovy for about $50/month. For Amazon One Medical launches weight

However, the initial FDA submission is for obesity only

The 2.5mg starting dose is subtherapeutic for weight loss

#Xanthine #CAS69896 #EnzymeActivity #BiochemicalResearch #PurineMetabolism #LaboratoryReagents #LifeScience To view or add a comment, sign in Discover How Untargeted Metabolomics Reveals Critical Stress Resolution Pathways Our latest case study uncovers the critical role of FASN cleavage in stress resolution, using untargeted metabolomics to identify key pathways in redox adaptation

102 102:382a, 2003

Later on, the FDA withdrew its approval in 2008 because of commercial reasons unrelated to its safety and efficacy